A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption.
J Med Chem
; 65(19): 13041-13051, 2022 10 13.
Article
in En
| MEDLINE
| ID: mdl-36134739
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ruthenium
/
Prodrugs
/
Carcinoma, Hepatocellular
/
Ferroptosis
/
Liver Neoplasms
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
J Med Chem
Journal subject:
QUIMICA
Year:
2022
Document type:
Article
Affiliation country:
China